L&K Biomed Participates in Chest Wall International Group for 3 Consecutive Years... Accelerates Global Expansion of "Pectus"

Participating in CWIG, introducing L&K Bio's chest wall deformity implant 'Pactus.' Provided by L&K Bio

L&K Biomed is accelerating its global market expansion by promoting its chest wall deformity implant, "Pectus." For three consecutive years, the company has participated in major international academic conferences attended by leading medical professionals in the chest wall field, highlighting the product’s technological capabilities and clinical cases. At the same time, it has been engaged in discussions for entering new markets such as Japan, the UK, and Germany, in addition to the United States.

L&K Biomed (CEO Kang Gukjin) announced on the 21st that its U.S. subsidiary, Aegis Meditech, INC, participated in the Chest Wall International Group (CWIG 2026), held in Leuven, Belgium, from September 14 to 17.

The Chest Wall International Group (CWIG) is an annual international academic conference where specialists in thoracic surgery, pediatric surgery, and plastic surgery share research and clinical experience on topics such as congenital chest wall deformities, chest wall resections, and reconstruction. L&K Biomed has participated for three consecutive years, expanding exchanges with global healthcare professionals.

At this year’s conference, Aegis Meditech joined as a major sponsor, meeting directly with hospital medical staff and stakeholders to introduce Pectus. By showcasing actual clinical experiences involving the product and recent achievements in the expanding Pectus business, they heightened global healthcare professionals’ interest in the brand.

From a technological perspective, the company highlighted one of Pectus’s core product lines: the “Pre Twisted End Bar.” This product was jointly developed with Cleveland Clinic, focusing on reducing the inconveniences of conventional methods that can arise during the “Cross Bar technique” surgical procedures.

In traditional procedures, the ends of the bar often had to be twisted and fixed directly inside the patient’s body. However, the Pre Twisted End Bar is pre-twisted during manufacturing, eliminating the need for additional manipulation by clinicians and allowing for safer fixation.

The company also introduced the “Sandwich Technique,” which can be applied depending on the patient’s specific type and condition of chest wall deformity. Alongside this, they shared clinical cases where this surgical method was applied using Pectus, further illustrating the versatility of the product.

Clinical experiences from world-renowned medical professionals in the field of chest wall surgery were also highlighted. Leading physicians such as Dr. John DiFiore, Dr. Dawn Jaroszewski, and Dr. Lisa McMahon, who have actually used L&K Biomed’s products in surgeries, presented cases of chest wall deformity correction using Pectus.

As these practitioners shared first-hand their clinical experiences with Pectus, the event not only showcased the technical features of the product but also helped demonstrate the feasibility of its clinical applications.

Discussions to expand into overseas markets also continued. With specialists from the U.S. and many other countries in attendance, L&K Biomed explored ways to supply the product and enter the markets of Japan, the UK, and Germany, among others. According to the company, participating medical professionals gave positive assessments of Pectus for its product quality and convenience of use.

An official from L&K Biomed remarked, “This conference is particularly significant because it was held after leading KOLs in the U.S. had rigorously used our Pectus products and experienced their excellence and broad range of surgical applications first-hand.”

They added, “We have successfully performed complex surgical cases that were previously difficult to address with competing products, further demonstrating the distinctive capabilities of our proprietary solutions. This event has offered an opportunity to propose a new therapeutic paradigm and build greater trust among both clinicians and patients.”

The company plans to maintain its revenue growth driven by the expanded supply of Pectus, while also increasing the scale of its global operations by entering new markets.

A company representative stated, “The supply of Pectus has recently ramped up significantly, and our sales are steadily increasing. It is important for us to sustain this growth trajectory.” He continued, “We will not remain complacent, but will further increase the share of Pectus in our sales portfolio and accelerate global business growth through new market entries.”

Beyond expanding product sales, L&K Biomed is also supporting the education of healthcare professionals in the field of chest wall surgery. The Chest Wall International Group educates medical staff in countries where the Nuss Bar technique has not yet become widespread, providing training in the latest surgical procedures and treatment methods, thereby helping raise medical standards globally.

L&K Biomed is in step with the goals of this conference by supporting healthcare professionals selected for overseas training and educational programs, enabling them to receive specialized chest wall surgery training in the United States. The company plans to contribute not only to the global expansion of its business but also to the wider development of chest wall disease treatment technology and to strengthening the expertise of international medical staff.

L&K Biomed intends to leverage its participation in the Chest Wall International Group conference to publicize the clinical experience and technological excellence of Pectus, expand overseas supply and entry into new markets, and thereby maintain global sales growth.

This content was produced with the assistance of AI translation services.